United States Pharmaceuticals

Inhibrx Biosciences Inc (INBX)

Track

Inhibrx Biosciences Inc. experienced significant insider activity on October 7, 2025, when Viking Global Investors LP executed multiple sell orders totaling over 350,000 shares. Prior to this, various executives engaged in buying throughout late 2024. As these transactions occurred more than three months ago, no assessment regarding current market valuation or performance is provided.
Ticker: INBX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Inhibrx Biosciences Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 7 Oct 2025
Value US$3,634,987.62 | Price 377.09 | Shares 4,175 (-4.1%)
Sale 7 Oct 2025
Value US$1,828,320.57 | Price 202.56 | Shares 76,763 (-39.5%)
Sale 7 Oct 2025
Value US$9,953,736.75 | Price 32.25 | Shares 308,643 (-19.6%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-10-09 2025-10-07 S Sale
3.2
VIKING GLOBAL INVESTORS LP
Large shareholder
4,175 -4.1%
377.09
US$3,634,988 		4,175 -4.1% 377.09 US$3,634,988
2025-10-09 2025-10-07 S Sale
3.2
VIKING GLOBAL INVESTORS LP
Large shareholder
76,763 -39.5%
202.56
US$1,828,321 		76,763 -39.5% 202.56 US$1,828,321
2025-10-09 2025-10-07 S Sale
3.2
VIKING GLOBAL INVESTORS LP
Large shareholder
37,493 -30.9%
304.61
US$993,308 		37,493 -30.9% 304.61 US$993,308
2024-11-22 2024-11-20 B Purchase
1.5
Kayyem Jon Faiz
Non-Executive Director
18,750 +36.7%
14.19
US$266,102 		18,750 +36.7% 14.19 US$266,102
2024-11-22 2024-11-20 B Purchase
1.5
Kayyem Jon Faiz
Non-Executive Director
18,750 +36.7%
14.19
US$266,102 		18,750 +36.7% 14.19 US$266,102
2024-11-22 2024-11-19 B Purchase
1.5
Kayyem Jon Faiz
Non-Executive Director
34,843 +214.4%
14.23
US$495,708 		34,843 +214.4% 14.23 US$495,708
2024-11-22 2024-11-19 B Purchase
1.5
Kayyem Jon Faiz
Non-Executive Director
34,843 +214.4%
14.23
US$495,708 		34,843 +214.4% 14.23 US$495,708
2024-10-07 2024-10-03 B Purchase
2.7
Vuori Kristiina MD
Non-Executive Director
6,667 +48.4%
15.00
US$100,005 		6,667 +48.4% 15.00 US$100,005
2024-09-16 2024-09-16 B Purchase
2.5
Lappe Mark

Chief Executive Officer

Executive Director
13,037 +1.9%
17.13
US$223,324 		13,037 +1.9% 17.13 US$223,324
2024-09-16 2024-09-12 B Purchase
2.5
Lappe Mark

Chief Executive Officer

Executive Director
26,963 +4.1%
15.05
US$405,793 		26,963 +4.1% 15.05 US$405,793
2024-09-12 2024-09-11 B Purchase
2.7
Vuori Kristiina MD
Non-Executive Director
6,457 +88.2%
15.07
US$97,307 		6,457 +88.2% 15.07 US$97,307
2024-09-12 2024-09-10 B Purchase
2.7
Vuori Kristiina MD
Non-Executive Director
179 +2.5%
15.00
US$2,685 		179 +2.5% 15.00 US$2,685
2024-09-10 2024-09-10 B Purchase
2.5
Lappe Mark

Chief Executive Officer

Executive Director
8,500 +1.3%
15.19
US$129,115 		8,500 +1.3% 15.19 US$129,115
2024-09-10 2024-09-09 B Purchase
2.5
Lappe Mark

Chief Executive Officer

Executive Director
9,500 +1.5%
15.21
US$144,495 		9,500 +1.5% 15.21 US$144,495
2024-09-10 2024-09-06 B Purchase
2.5
Lappe Mark

Chief Executive Officer

Executive Director
26,000 +4.2%
15.29
US$397,540 		26,000 +4.2% 15.29 US$397,540
2024-09-03 2024-09-03 B Purchase
2.5
Lappe Mark

Chief Executive Officer

Executive Director
4,712 +2.9%
16.31
US$76,853 		4,712 +2.9% 16.31 US$76,853
2024-09-03 2024-09-03 B Purchase
2.5
Lappe Mark

Chief Executive Officer

Executive Director
15,288 +10.5%
15.66
US$239,410 		15,288 +10.5% 15.66 US$239,410
2024-09-03 2024-08-30 B Purchase
2.5
Lappe Mark

Chief Executive Officer

Executive Director
10,000 +7.4%
14.02
US$140,200 		10,000 +7.4% 14.02 US$140,200
2024-09-03 2024-08-29 B Purchase
2.5
Lappe Mark

Chief Executive Officer

Executive Director
10,000 +8.0%
14.03
US$140,300 		10,000 +8.0% 14.03 US$140,300
2024-09-03 2024-08-29 B Purchase
2.7
Vuori Kristiina MD
Non-Executive Director
7,140 +inf%
14.00
US$99,960 		7,140 +inf% 14.00 US$99,960
2024-08-30 2024-08-28 B Purchase
3.0
MANHARD KIMBERLY
Non-Executive Director
10,000 +inf%
13.98
US$139,800 		10,000 +inf% 13.98 US$139,800
2024-08-26 2024-08-23 B Purchase
2.8
FORSYTH DOUGLAS
Non-Executive Director
59,812 +36.3%
14.07
US$841,555 		59,812 +36.3% 14.07 US$841,555
2024-08-26 2024-08-22 B Purchase
2.8
FORSYTH DOUGLAS
Non-Executive Director
15,188 +10.2%
12.89
US$195,773 		15,188 +10.2% 12.89 US$195,773
2024-08-22 2024-08-21 B Purchase
2.5
Lappe Mark

Chief Executive Officer

Executive Director
12,945 +30.9%
12.93
US$167,379 		12,945 +30.9% 12.93 US$167,379
2024-08-22 2024-08-20 B Purchase
2.5
Lappe Mark

Chief Executive Officer

Executive Director
27,055 +182.0%
12.97
US$350,903 		27,055 +182.0% 12.97 US$350,903
2024-06-07 2024-06-05 B Purchase
1.5
Kayyem Jon Faiz
Non-Executive Director
8,265 +0.7%
17.89
US$147,861 		8,265 +0.7% 17.89 US$147,861
2024-06-07 2024-06-05 B Purchase
1.5
Kayyem Jon Faiz
Non-Executive Director
49,284 +4.5%
17.23
US$849,163 		49,284 +4.5% 17.23 US$849,163
2024-06-04 2024-06-04 B Purchase
1.5
Kayyem Jon Faiz
Non-Executive Director
23,726 +2.2%
18.24
US$432,762 		23,726 +2.2% 18.24 US$432,762
2024-06-04 2024-06-04 B Purchase
1.5
Kayyem Jon Faiz
Non-Executive Director
65,337 +6.5%
17.44
US$1,139,477 		65,337 +6.5% 17.44 US$1,139,477
2024-06-04 2024-06-03 B Purchase
1.5
Kayyem Jon Faiz
Non-Executive Director
80,738 +8.7%
17.90
US$1,445,210 		80,738 +8.7% 17.90 US$1,445,210
2024-06-04 2024-06-03 B Purchase
1.5
Kayyem Jon Faiz
Non-Executive Director
46,792 +5.3%
16.61
US$777,215 		46,792 +5.3% 16.61 US$777,215
2024-06-04 2024-05-31 B Purchase
1.5
Kayyem Jon Faiz
Non-Executive Director
70,193 +8.7%
16.14
US$1,132,915 		70,193 +8.7% 16.14 US$1,132,915
Explore more

More insider trading research around Inhibrx Biosciences Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America